Life-threatening COVID-19 in a thymoma patient with anti-interferon-α autoantibodies.

ingentiumby ingentium

In Clinical Literature.

Publication date: Feb 05, 2025

Neutralizing anti-interferon (IFN)-α autoantibodies can lead to immune dysregulation, potentially resulting in critical coronavirus disease 2019 (COVID-19). We report a case presenting with severe COVID-19 who was subsequently diagnosed to have thymoma and neutralizing anti-IFN-α autoantibodies.

Open Access PDF

Concepts Keywords
Coronavirus Anti-IFN-α autoantibodies
Covid Critical COVID-19
Dysregulation Thymoma
Immunol Type 1 interferons
Viral infections

Semantics

Type Source Name
disease MESH COVID-19
disease MESH thymoma
disease MESH Infection
drug DRUGBANK Guanosine
disease MESH Viral infections
disease MESH influenza
disease MESH Syndrome
disease MESH herpes simplex
disease IDO production
disease MESH emergency
disease MESH sore throat
disease IDO history
disease MESH pemphigus vulgaris
drug DRUGBANK Rituximab
disease IDO blood
drug DRUGBANK Oxygen
drug DRUGBANK Dexamethasone
drug DRUGBANK Tocilizumab
disease MESH tumor
drug DRUGBANK Acetylcholine
drug DRUGBANK Coenzyme M
disease MESH myasthenia gravis
disease MESH hypogammaglobulinemia
disease MESH opportunistic infections
disease MESH viral shedding
disease MESH lymphocytopenia
drug DRUGBANK Natural alpha interferon
disease MESH convalescence
disease MESH critically ill
drug DRUGBANK Immune Globulin Human
disease IDO cell
disease MESH recurrent infection
disease IDO protein
disease IDO susceptibility
drug DRUGBANK Yellow Fever Vaccine
disease MESH etiology
disease MESH clinical significance
disease MESH thymic tumors
disease MESH autoimmune diseases
disease MESH infectious disease
pathway REACTOME Infectious disease
disease MESH pneumonia
disease MESH yellow fever

Original Article

(Visited 3 times, 1 visits today)